HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Brock, C.S. Articles by Lee, S.M. Search for Related Content PubMed PubMed Citation Articles by Brock, C.S. Articles by Lee, S.M.

Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer

Meyerstein Institute of Oncology, Middlesex/University College London Hospitals, Mortimer Street, London, UK

CORRESPONDENCE: C.S. Brock, CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Block E, Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, UK. Fax: 44 2086427979. E-mail: cbrock@icr.ac.uk

Keywords: anti-angiogenesis, lung cancer, vascular targeting

Received: November 7, 2001
Accepted November 27, 2001

Abstract

The generation of new blood vessels, angiogenesis, is important for tumour proliferation and metastasis. This involves a number of interacting processes and factors, such as growth factors and the receptor tyrosine kinases, matrix metalloproteinases and integrins.

Studies have shown that tumour vascularity and the overexpression of growth factors and their receptors are of independent prognostic importance in different cancers, including lung cancer.

The present article provides a background to angiogenesis and describes the potential targets for anti-angiogenic and vascular targeting strategies in cancer, focusing specifically on carcinoma of the lung. It also describes the anti-angiogenic drugs presently under phase I, II and III investigation and highlights some of the problems associated with the standard methodologies for assessing tumour response and drug efficacy using these agents.

This article has been cited by other articles:

				K. L. DeCicco, T. Tanaka, F. Andreola, and L. M. De Luca The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPAR{gamma} pathway Carcinogenesis, October 1, 2004; 25(10): 1805 - 1812. [Abstract] [Full Text] [PDF]

				K.-i. Inoue, Y. Kawahito, H. Sano, H. Takano, and T. Yoshikawa New Diagnostic Tool for Tumor Angiogenesis Chest, March 1, 2003; 123(3): 966 - 967. [Full Text] [PDF]